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Protein kinase CK2 phosphorylates and activates 
p21-activated kinase 1
Yong Jae Shin, Yong-Bae Kim, and Jeong-Ho Kim
Department of Biochemistry and Molecular Medicine, George Washington University Medical Center, Washington, DC 
20037
ABSTRACT Activation of the p21-activated kinase 1 (PAK1) is achieved through a conforma-
tional change that converts an inactive PAK1 dimer to an active monomer. In this paper, we 
show that this change is necessary but not sufficient to activate PAK1 and that it is, rather, 
required for CK2-dependent PAK1S223 phosphorylation that converts a monomeric PAK1 into 
a catalytically active form. This phosphorylation appears to be essential for autophosphoryla-
tion at specific residues and overall activity of PAK1. A phosphomimetic mutation (S223E) 
bypasses the requirement for GTPases in PAK1 activation, whereas the constitutive activity of 
the PAK1 mutant (PAK1H83,86L), postulated to mimic GTPase-induced structural changes, is 
abolished by inhibition of S223 phosphorylation. Thus, S223 is likely accessible to CK2 upon 
conformational changes of PAK1 induced by GTPase-dependent and GTPase-independent 
stimuli, suggesting that S223 phosphorylation may play a key role in the final step of the 
PAK1 activation process. The physiological significance of this phosphorylation is reinforced 
by the observations that CK2 is responsible for epidermal growth factor–induced PAK1 acti-
vation and that inhibition of S223 phosphorylation abrogates PAK1-mediated malignant 
transformation of prostate epithelial cells. Taken together, these findings identify CK2 as an 
upstream activating kinase of PAK1, providing a novel mechanism for PAK1 activation.
INTRODUCTION
P21-activated kinases (PAKs) are downstream effectors of the small 
GTPases Cdc42 and Rac, molecular switches that transduce various 
extracellular signals into intracellular responses (Manser et al., 1994). 
To date, six PAK family members have been identified and subdi-
vided into two groups on the basis of their structural and biochemi-
cal features (Bokoch, 2003; Arias-Romero and Chernoff, 2008): 
group I (PAK1–3) and group II (PAK4–6). PAK1, the best-character-
ized member of the PAK family, is regulated by autoinhibition 
imposed on the C-terminal catalytic domain by the N-terminal auto-
inhibitory domain (AID; Lei et al., 2000; Parrini et al., 2002). This au-
toinhibition is relieved upon binding of activated GTPases to the 
p21-binding domain/Cdc42/Rac-interacting domain (PBD/CRIB do-
main) that partially overlaps with AID, leading to PAK1 activation 
(Morreale et al., 2000). However, group II PAKs do not contain the 
AID, and thus GTPases have little effect on kinase activity (Pandey 
et al., 2002).
Group I PAKs are also activated by various mechanisms indepen-
dent of GTPases (Field and Manser, 2012). PAK1 is recruited to the 
plasma membrane via the SH3-containing proteins Nck and Grb2 
(Bokoch et al., 1996), where it is activated by signaling molecules 
such as PDK1 kinase (King et al., 2000), sphingolipids (Zenke et al., 
1999), and PIP2 (Strochlic et al., 2010). PAK2 is activated through 
proteolytic cleavage by caspases, liberating the N-terminal AID and 
thereby generating an active C-terminal catalytic domain (Rudel and 
Bokoch, 1997). PAK3 is unique among PAKs because it exists as 
four alternatively spliced isoforms activated in different manners 
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et al., 1994), the kinase-dead (KD) PAK1 (PAK1K299R) was generated 
with a point mutation (GST-PAK1-KD) and used for phosphorylation 
assays. We found that CK2α knockdown does not affect PAK1 ex-
pression but significantly decreases PAK1 phosphorylation (Figure 
1B) and that phosphorylation of GFP-PAK1-KD is inhibited by treat-
ment of the CK2 inhibitor TBB (Figure 1C). Purified CK2α was shown 
to phosphorylate bacterially produced wild-type PAK1 protein (GST-
PAK1-KD) but not mutant PAK1 protein (GST-PAK1S223A-KD) in vitro 
(Figure 1D); however, this phosphorylation was also significantly in-
hibited by treatment of the CK2 inhibitor heparin in a dose-depen-
dent manner (Figure 1E).
PAK1 activity is critically regulated by CK2-dependent S223 
phosphorylation
Given that increased PAK1 activity is associated with autophos-
phorylation of specific sites, including S144 and S199 (Chong 
et al., 2001), we examined whether S223 phosphorylation affects 
the kinase activity of PAK1. Our results showed that S223A muta-
tion or CK2α knockdown inhibits phosphorylation of those resi-
dues (Figure 2, A and B, top panels) and reduces PAK1 kinase ac-
tivity, as determined by in vitro phosphorylation assay using myelin 
basic protein (MBP) as a substrate (Figure 2, A and B, bottom pan-
els). We further examined the significance of PAK1S223 phosphory-
lation in cell growth and found that proliferation of human prostate 
RWPE-1 (Figure 2C, left) and human breast MCF10A (Figure 2C, 
right) cells was enhanced by expression of wild-type PAK1 but not 
of mutant PAK1 (PAK1S223A). Similar observations were made in 
mouse NIH 3T3 and Rat1 cells (Figure S2), suggesting that S223 
phosphorylation may be a general requirement for PAK1 activa-
tion. Phosphorylation of T423 in the activation loop of PAK1 is im-
portant for PAK1 activation, but this phosphorylation does not 
readily occur; rather, it is catalyzed by PDK1 at the plasma mem-
brane in a GTPase-independent manner (King et al., 2000). S223A 
mutation did not affect T423 phosphorylation (Figure 2A); T423A 
mutation also did not regulate S223 phosphorylation (Figure 2D), 
suggesting that S223 and T423 are phosphorylated by different 
signaling pathways. However, in a comparison of the effects of 
S223A and T423A mutations on PAK1-induced cell invasion, we 
found that S223A mutation is more severe than T423A mutation 
(Figure 2, E and F).
To directly assess the phosphorylation state of PAK1S223, 
we generated a phospho-PAK1 (S223) antibody (pPAK1S223) and 
determined the specificity of the antibody by dot blot analysis 
(Figure 3A) and by Western blot analysis of S223 phosphorylation 
of PAK1 (WT), PAK1S223A, and PAK1S223E (Figure 3B). Serum-stimu-
lated phosphorylation of S223 was shown to be inhibited by CK2α 
knockdown (Figure 3C) or TBB treatment (Figure 3D), confirming 
that S223 of PAK1 is a CK2 target in vivo. We further examined the 
time course of PAK1 phosphorylation by CK2 and found that phos-
phorylation of S223 and S144 is enhanced by treatment of serum 
but inhibited by CK2α knockdown (Figure 3E) in a similar manner 
(Figure 3F).
CK2-catalyzed PAK1S223 phosphorylation may constitute a 
novel mechanism for regulation of PAK1 activity
To understand the role of PAK1S223 phosphorylation in the regula-
tion of PAK1 activity, we first assessed the autophosphorylation ac-
tivity of the PAK1 mutant with glutamic acid substituted at S223 
(PAK1S223E). The results showed that S144 phosphorylation of 
PAK1S223E is strongly detected (Figure 4A) and, more importantly, 
that this phosphorylation occurs independent of CK2 (Figure 4B). 
Thus, the S223E mutation likely mimics phosphorylation of S223, 
(Kreis et al., 2008). Thus, PAKs are likely regulated by different 
mechanisms that operate independently.
PAK1 plays fundamental roles in various cellular processes, in-
cluding actin cytoskeleton dynamics (Edwards et al., 1999), apopto-
sis (Vadlamudi et al., 2004), histone modification (Li et al., 2002), and 
cell cycle progression (Zhao et al., 2005). PAK1 does so by acting as 
a convergence point of many signaling pathways that are frequently 
dysregulated in human cancer and appears to be widely overex-
pressed and hyperactivated in various cancer cells (Kumar et al., 
2006). Consistent with these observations, overexpression of an ac-
tivated mutant form of PAK1 leads to the formation of mammary 
gland tumors in a transgenic mouse model (Wang et al., 2006a). 
However, in some cell types, including prostate cells, there is no 
significant difference in PAK1 mRNA expression between normal 
and malignant tissues (GeneCards, www.genecards.org), suggest-
ing the existence of a distinct mechanism for the conversion of PAK1 
from an inactive to an active form through posttranslational mecha-
nisms in those cells.
CK2 is a ubiquitously expressed protein kinase and regulates a 
wide variety of biological processes, including cell growth and sur-
vival, gene expression, and actin cytoskeleton organization (Meggio 
and Pinna, 2003). CK2 is overexpressed in cancer cells and promotes 
tumorigenesis by regulating the stability and/or activity of tumor 
suppressors and by perpetuating multiple cell survival signaling 
pathways. CK2 is also membrane targeted and acts directly on actin 
or actin-associated proteins such as WASP (Cory et al., 2003) and 
CRN2 (Xavier et al., 2012), regulating actin polymerization. This 
study reveals that CK2 kinase plays a key role in regulating PAK1 
activity. The prevailing view is that PAK1 is activated through conver-
sion of PAK1 from an inactive dimer to an active monomer. In this 
paper, we provide evidence that this conversion is necessary but not 
sufficient to bring about full activation of PAK1 and that it is, rather, 
required for CK2-dependent PAK1 phosphorylation, enabling the 
kinase domain of PAK1 to be catalytically competent.
RESULTS
CK2 phosphorylates PAK1 at S223
The observations that CK2 and PAK1 both are often activated by 
the same external stimuli, including growth factors, and that PAK1 
contains several putative CK2 phosphorylation sites (Meggio and 
Pinna, 2003) support a hypothesis that CK2 may directly phospho-
rylate and activate PAK1. For testing this hypothesis, green fluores-
cent protein (GFP)-PAK1 expressed in 293T cells with or without 
CK2α knockdown was immunoprecipitated with anti-GFP antibody 
and processed for liquid chromatography–tandem mass spectrom-
etry (LC-MS/MS) analysis (Figure 1 and Supplemental Figure S1A). 
Data analysis with MASCOT and Scaffold software identified a pep-
tide that matches 215RDVATSPISPTENNTTPPDAL235, indicating that 
S223 (underlined) is modified by phosphorylation (Figure 1A, top, 
arrow). The observation that this phosphorylation is not detected in 
the peptide derived from PAK1 expressed in CK2α knockdown cells 
(Figure 1A, bottom) indicated that S223 phosphorylation is CK2 de-
pendent. Consistent with this notion, S223 lies within a canonical 
CK2 phosphorylation site, S/T-X-X-E/D/Ps (Meggio and Pinna, 2003; 
Diella et al., 2008) and appears to be conserved in mammalian 
PAK1 proteins (Figure S1B). Interestingly, however, S223 is not 
found in other members of the PAK family but is unique to PAK1 
(Figure S1C).
To obtain further evidence of CK2-catalyzed PAK1S223 phospho-
rylation, we infected 293T cells with lentivirus expressing GFP-PAK1 
and metabolically labeled them with [32P]orthophosphate. Because 
wild-type PAK1 possesses autophosphorylation activity (Manser 
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autoinhibitory conformation of PAK1. In addition, we confirmed 
that the S223A mutation does not impair the binding of PAK1 to 
Rac1 (Figure S3A) and that CK2 does not regulate Rac1 activity 
(Figure S3B).
We also examined whether S223 phosphorylation is required for 
PAK1 activation in a GTPase-independent manner. The H83,86L 
double mutation impairs the binding of PAK1 to GTPases but does 
not inhibit its activity, illustrating that this mutation mimics activa-
tion by GTPases and that PAK1 can also be activated in a GTPase-
independent manner (Sells et al., 1997). We found that the effect of 
the double mutation (H83,86L) on S144 phosphorylation is abol-
ished by the additional mutation of S223A (Figure 4D, H83,86L/
S223A).
suggesting that this mutation may convert PAK1 into a constitutively 
active form. The binding of PAK1 to Cdc42 and Rac to the CRIB 
domain results in release of the autoinhibition and conversion of the 
dimeric PAK1 to a monomeric form (Lei et al., 2000). Therefore, a 
mutation of S76 (S76A) located in the CRIB domain renders PAK1 
inactive by impairing its binding to GTPases (Zhao et al., 1998). We 
found that the S76A mutation impairs phosphorylation of S223 and 
S144, but that this inhibition is abolished by the S76A/S223E double 
mutation (Figure 4C, pPAK1S144). Notably, the dimer-to-monomer 
conversion of PAK1 was inhibited by the S76A mutation, whereas it 
was not affected by the S223A mutation (Figure 4E). Therefore, it is 
likely that S223 becomes available for phosphorylation upon the 
binding of GTPases to the CRIB domain, leading to release of the 
FIGURE 1: CK2 phosphorylates PAK1 on S223. (A) Mass spectrometry identification of CK2-catalyzed PAK1 
phosphorylation at S223. The 293T cells treated with a nontargeting shRNA (NT, top) or a CK2α-specific shRNA (shRNA, 
bottom) were infected with lentivirus expressing GFP-PAK1. GFP-PAK1 was immunoprecipitated with anti-GFP 
antibody, resolved by SDS–PAGE, and digested with trypsin or chymotrypsin/elastase. The resulting eluted peptides 
were analyzed directly by LC-MS/MS. The m/z difference between y-13s (arrows) of the peptides derived from 293T 
cells with (bottom) or without (top) CK2α knockdown indicates a phosphoserine at position 223. (B) Effect of CK2α 
knockdown on PAK1 phosphorylation in vivo. Western blot analysis of expression of GFP-PAK1-KD, CK2α, and actin in 
293T cells with (sh1 and sh2) or without (NT) CK2α knockdown (WB). The 293T cells expressing GFP-PAK1-KD were 
metabolically labeled with [32P]orthophosphate. GFP-PAK1-KD was immunoprecipitated with anti-GFP antibody and 
analyzed by autoradiography. (C) Effect of the CK2 inhibitor TBB on PAK1 phosphorylation in vivo. The 293T cells 
expressing GFP-PAK1-KD were treated with different concentrations of TBB, as indicated above each lane, and 
metabolically labeled with [32P]orthophosphate. (D) In vitro phosphorylation of PAK1 by CK2. Bacterially expressed 
GST-PAK1-KD or GST-PAK1-KD-S223A was incubated with purified CK2 holoenzyme (20 ng) and [32P]γ-ATP and analyzed 
by autoradiography. (E) Effect of the CK2 inhibitor heparin on PAK1 phosphorylation in vitro. Bacterially expressed 
GST-PAK1-KD was incubated with purified CK2 holoenzyme (20 ng) and [32P]γ-ATP in the absence and presence of 
different amounts of heparin (lane 3: 25 μg; lane 4: 5 μg; lane 5: 1 μg) for 30 min and analyzed by autoradiography.
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while it did not affect PAK1 expression (Figure 5A). Recent studies 
show that CK2 is a component of the kinase suppressor of Ras 
(KSR1) scaffolding complex associated with the plasma membrane 
that facilitates the ERK cascade (Ritt et al., 2007) and that the activity 
of a subcellular portion of CK2 is enhanced by epidermal growth 
factor receptor (EGFR)-ERK signaling (Ji et al., 2009). Thus, we 
CK2 is responsible for epidermal growth factor (EGF)-
induced PAK1 activation
To understand the regulation of PAK1 activity by S223 phosphoryla-
tion in cancer cell growth, we first assessed autophosphorylation of 
endogenous PAK1 in the prostate cancer cell line PC3. CK2α knock-
down was shown to decrease phosphorylation of S144 and S199, 
FIGURE 2: CK2-catalyzed PAK1S223 phosphorylation is required for autophosphorylation and activity of PAK1. The 293T 
cells were transiently transfected with wild-type or mutant PAK1 protein, and cell extracts were subjected to Western 
blot analysis with phospho-specific PAK1 antibodies. The same blots were stripped and reprobed with anti-GFP 
antibody to control for equal protein loading. (A) Western blot analysis of phosphorylation of S144, S199, and T423 of 
GFP-PAK1 (WT) or GFP-PAK1S223A. The kinase activity of PAK1 (GFP-PAK1 [WT]) and GFP-PAK1S223A) was assessed by in 
vitro phosphorylation assay using MBP as a substrate (bottom). (B) Western blot analysis of phosphorylation of 
GFP-PAK1 expressed in 293T cells with (sh1 and sh2) or without (NT) CK2α knockdown with anti-pPAK1S144 antibody 
(pPAK1S144). Top, Western blot analysis of expression of CK2α (CK2α). Actin was used as a loading control (Actin). 
Bottom, in vitro phosphorylation of MBP by GFP-PAK1 immunoprecipitated with anti-GFP antibody from extracts of 
293T cells with (sh1) or without (NT) CK2α knockdown. (C) MTT proliferation assays of RWPE-1 (left) and MCF 10A 
(right) cells. Cell viability over time was expressed as fold increase over untreated control at day 1. Error bars represent 
mean ± SD (n = 5). Insets: Western blot analysis of expression of GFP-PAK1 (WT) or GFP-PAK1S223A. (D) Western blot 
analysis of phosphorylation of T423, S223, and S199 of GFP-PAK1 (WT) or GFP-PAK1T423A. (E) PAK1-induced cell 
invasion. The benign prostate RWPE-1 cells infected with lentivirus expressing the vector plasmid, GFP-PAK1 (WT), 
GFP-PAK1S223A (S223A), or GFP- PAK1T423A (T423A) were used for invasion assays. (F) The invasion rate was determined 
by counting the cells that migrated through BME-coated inserts in the Transwell Boyden chamber and expressed as the 
percentage relative to control (vector). Each bar represents the mean ± SD of five fields counted.
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lines (Vadlamudi et al., 2000) and is sufficient for the formation of 
mammary gland tumors in a transgenic mouse model (Wang et al., 
2006b). To further understand the significance of S223 phosphoryla-
tion in PAK1-mediated cellular transformation, we compared the 
ability of wild-type (GFP-PAK1) and mutant (GFP-PAK1-S223A) PAK1 
proteins to transform the human prostate epithetical cell line 
RWPE-1 to a tumorigenic phenotype in culture (Figure 2C, left, in-
set). Cell proliferation was enhanced by expression of wild-type 
PAK1 but not of mutant PAK1 (PAK1S223A), as shown in 3-[4,5-dime-
thylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT; Figure 2C, 
left) and foci-forming (Figure 6A) assays, respectively. It was also 
demonstrated that, in contrast to expression of PAK1, expression of 
PAK1S223A is neither able to induce anchorage-independent growth 
of (Figure 6B) nor to confer an invasive phenotype to (Figure 6C) 
RWPE-1 cells. For investigation of the transforming activity of PAK1 
in vivo, RWPE-1 cells expressing PAK1 or PAK1S223A were subcutane-
ously injected into the flanks of nude mice (Figure S4), and the mice 
were killed 6 wk afterward. Progressive tumor growth was observed 
in mice injected with RWPE-1 cells expressing PAK1 but not 
PAK1S223A (Figure 6, D and E). Immunohistochemical analysis of the 
tumor tissues dissected from the mice demonstrated the expression 
examined the possible connection between PAK1 and the EGFR-
ERK-CK2 pathway by determining the deletion effect of CK2α on 
the PAK1 autophosphorylation in EGF-stimulated PC3 cells. The re-
sults showed that CK2α knockdown inhibits EGF-induced PAK1 
phosphorylation at both S223 and S144 (Figure 5B).
PAK1 is the major isoform of PAKs expressed in most cancers (Ye 
and Field, 2012). The fact that S223 of PAK1 is not conserved in 
other PAK family members (Figure S1C) led to an idea that CK2-
mediated PAK1 phosphorylation enables PAK1 to be the principal 
PAK isoform in cancer cells. To test the relative significance of PAKs 
in tumor cell growth, we investigated the effect of PAK1 and PAK2 
knockdowns on the growth of the prostate cancer cell line PC3. The 
results indicated that knockdown of PAK1, but not of PAK2, is suffi-
cient to inhibit the growth of PC3 cells (Figure 5C) and are consistent 
with previous reports that PAK1 promotes prostate tumor growth 
(Goc et al., 2013).
Inhibition of S223 phosphorylation abrogates PAK1-
mediated malignant transformation
Overexpression of an activated mutant form of PAK1 leads to the 
stimulation of anchorage-independent growth in breast cancer cell 
FIGURE 3: Verification of CK2-dependent PAK1S223 phosphorylation by Western blot analysis using anti-pPAK1S223 
antibody. (A) Dot blot analysis of a newly generated phospho-PAK1 (S223) antibody (pPAK1S223). The phospho-PAK1 
peptide (214–227; TRDVATSPI-pSer-PTEN) was untreated or treated with calf intestinal phosphatase and incubated with 
anti-pPAKS223 and anti-PAK1 antibodies. Signals were detected by chemiluminescence detection reagents. (B) Western 
blot analysis of phosphorylation of S223 of PAK1 (WT), PAK1S223A, and PAK1S223E. (C) GFP-PAK1–expressing 293T cells 
were treated with (sh1) or without (NT) CK2α knockdown. The cells were incubated for 1 d in the absence of serum and 
then cultured in the presence (+) or absence (−) of serum for 15 min. Cell lysates were subjected to Western blot 
analysis with anti-pPAK1S223. (D) Western blot analysis of phosphorylation of PAK1S223 in 293T cells treated with TBB 
(lane 2: 1 μM; lane 3: 5 μM; lane 4: 20 μM) with anti-pPAK1S223 or anti-GFP antibody. (E) 293T cells with (sh1) or without 
(NT) CK2α knockdown were infected with lentivirus expressing GFP-PAK1. Cells were incubated for 1 d in the absence 
of serum and then cultured in the presence of serum for different periods of time, as indicated above each lane, and 
cell extracts were subjected to Western blot analysis with anti-pPAK1S223 or anti-pPAK1S144 antibody. The same 
membrane was then stripped and reprobed with anti-PAK1 antibody. (F) Densitometry analysis of results shown in (E). 
The signals of pPAK1S223 in the immunoblot were quantified by scanning densitometry and normalized to the signals of 
total GFP-PAK1. Each point represents the mean value of three independent assays, with error bars indicating the SD.
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as a key regulator of cell adhesion and motility, is targeted to the 
plasma membrane upon stimulation (Parrini et al., 2005). Once re-
cruited, PAK1 associates with Cdc42 and Rac1 and is activated at 
the membrane. CK2 is ubiquitously expressed but redistributed to 
various cellular compartments upon stimulation (Meggio and Pinna, 
2003); its recruitment to the plasma membrane is mediated by the 
CK2α interacting partner CKIP-1 (Canton et al., 2006). Thus, CK2-
dependent PAK1 activation may provide a framework for spatiotem-
poral regulation of PAK1, as proposed previously (Parrini et al., 
2005). Sphingosine positively regulates CK2 activity (McDonald 
et al., 1991) and activates PAK1 in a GTPase-independent manner 
(Zenke et al., 1999); moreover, sphingosine 1-phosphate, a deriva-
tive of sphingosine, activates ERK1/2 (Maupas-Schwalm et al., 2004; 
Catarzi et al., 2011), which in turn phosphorylates and activates CK2 
(Ji et al., 2009). These observations may support our findings that 
CK2 is responsible for EGF-induced PAK1 activation and the view 
that CK2 plays a key role in integrating both GTPase-dependent 
and GTPase-independent signals to regulate PAK1 activity.
The process of PAK1 activation entails two major events: 1) con-
version of a PAK1 dimer to a monomer and relief of autoinhibition; 
and 2) activation of the catalytic domain and autophosphorylation at 
specific residues for full activation of PAK1. A phosphomimetic mu-
tation (S223E) bypasses the requirement for GTPases in PAK1 acti-
vation, suggesting that CK2 phosphorylation of PAK1S223 may be a 
key regulatory step for PAK1 activation. In addition, membrane-tar-
geted PAK1 can be activated in the absence of stimulation of Rho 
family GTPases (Lu et al., 1997), supporting the view that aberrant 
activation of this phosphorylation may bypass the requirement for 
GTPases. The PAK1 mutant (PAK1H83,86L) postulated to mimic 
GTPase-induced structural changes is constitutively active (Sells 
et al., 1997); however, the kinase activity of the activated PAK1 mu-
tant is abolished by inhibiting S223 phosphorylation of the protein 
(Figure 4). Thus, S223 likely becomes available for phosphorylation 
by CK2 after conformational changes induced by GTPase-depen-
dent and GTPase-independent stimuli. This notion may be sup-
ported by the observation that PAK1 contains potential phosphory-
lation sites that become accessible upon activation by Cdc42 or Rac 
(Hoffman et al., 2000). Based on our observations, we surmise that 
S223 phosphorylation may be important for locking PAK1 in a cata-
lytically competent conformation and keeping it in an activated state 
by serving as a priming event for subsequent phosphorylation. We 
anticipate that a structural analysis would yield a better understand-
ing of the exact role of S223 phosphorylation in PAK1 activation.
PAK1 phosphorylation at T423 in the activation loop in the kinase 
domain, which is mediated by PDK1 (Zenke et al., 1999; King et al., 
2000), plays a role in stabilizing the active site (Lei et al., 2005). The 
tumor suppressor phosphatase and tensin homologue deleted on 
chromosome 10 (PTEN) dephosphorylates phosphatidylinositol-
3,4,5-phosphate, down-regulating the PI3K/Akt signaling; CK2 
phosphorylates PTEN and reduces PTEN activity (Vazquez et al., 
2000; Torres and Pulido, 2001; Al-Khouri et al., 2005), leading to 
activation of PDK1 (Ruzzene and Pinna, 2010). Hence, it may be pos-
sible that, in addition to phosphorylation at S223, CK2 also regu-
lates PAK1 activity by promoting phosphorylation of T423 via the 
PI3K/Akt signaling (Figure 7).
Activation of oncogenic kinases by elevated expression is a 
common feature of human primary tumors. However, there is no 
significant difference in PAK1 expression between normal and can-
cerous prostate cells. A similar pattern of PAK1 expression is also 
observed in various cell types, including pancreas, kidney, lung, 
thymus, bone marrow, and brain (GeneCards). These observations 
suggest that hyperactivation of PAK1 in these cancer cells is not 
of GFP-PAK1, the proliferation marker Ki67 and the angiogenic 
marker CD31 (Figure 6F), and the phosphorylation of PAK1S223 
(Figure 6G). These results establish for the first time that PAK1 over-
expression is sufficient for the malignant transformation of epithelial 
prostate cells and support the view that S223 phosphorylation is 
critical for the transforming activity of PAK1.
DISCUSSION
The functional significance of PAK1 in cell migration and survival has 
long been appreciated (Kumar et al., 2006), but the underlying 
mechanism of PAK1 activation is not clearly understood. This is 
mainly due to the fact that PAK1 can be activated in response to a 
variety of external signals by GTPase-dependent and GTPase-inde-
pendent mechanisms. The critical question in these mechanisms is 
how these signals are integrated to bring about efficient activation 
of PAK1. In this study, we provide evidence that CK2 has an impor-
tant role in integrating these signals and functions as an upstream 
activating kinase of PAK1: 1) CK2 phosphorylates PAK1 at S223 in 
vivo and in vitro (Figure 1); 2) S223 phosphorylation plays a key role 
in the final step of the PAK1 activation process (Figures 2–4); 3) this 
phosphorylation is unique to PAK1 among PAK family members, but 
sufficient for oncogenic conversion of PAK1 (Figures 5 and 6). PAK1, 
FIGURE 4: CK2-dependent PAK1S223 phosphorylation is required 
for PAK1 activation by both GTPase-dependent and GTPase-
independent mechanisms. (A) Western blot analysis of 
phosphorylation of S144 of PAK1 (WT), PAK1S223A, and PAK1S223E. 
The same blots were stripped and reprobed with anti-GFP antibody 
to control for equal protein loading. (B) GFP-PAK1 (WT) or GFP-
PAK1S223E was expressed in 293T cells with (sh1) and without (NT) 
CK2α knockdown, and cell extracts were subjected to Western blot 
analysis with anti-pPAK1S144 or anti-GFP antibody. (C) Western blot 
analysis of phosphorylation of S144 and S223 of GFP-PAK1 (WT), 
GFP-PAK1S76A, and GFP-PAK1S76A/S223E. (D) Western blot analysis of 
phosphorylation of S144 and S223 of GFP-PAK1 (WT), GFP-
PAK1H83,86L, or GFP-PAK1H83,86L/S223A. (E) The 293T cells were 
transiently transfected with GFP-PAK1 (WT), GFP-PAK1S76A, or with 
GFP-PAK1S223A, and cell extracts were resolved in 8% native PAGE 
gels. The immunoblots were probed with anti-GFP antibody.
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MATERIALS AND METHODS
Cell culture
Benign prostate epithelial cell line RWPE-1 
cells were grown in keratinocyte serum-
free medium (K-SFM) containing bovine 
pituitary extract and EGF, as described 
previously (Shin and Kim, 2012). The 
human embryonic kidney cell line 293T 
and the human prostate cancer cell line 
PC3 were cultured in RPMI 1640 or DMEM 
containing 10% fetal bovine serum (FBS) 
and penicillin/streptomycin at 37°C in a 
humidified atmosphere of 5% CO2.
Cell invasion
Cell invasion assay was performed using 
the cell invasion kit (Transwell Boyden’s 
chamber with Transwell Permeable Sup-
port Inserts Coated with Cultrex base-
ment membrane extract [BME]; Corning 
Costar, Cambridge, MA) according to the 
manufacturer’s instruction (Shin and Kim, 
2012).
Soft agar assay
For soft agar assays, anchorage-indepen-
dent growth was deter mined in six-well 
plates. A lower-layer plug of 0.6% agar 
solution in K-SFM containing 2 μg/ml of 
puromycin was prepared. This was over-
laid with 3 ml of a 0.3% agar solution, also 
in RWPE-1, with 3 × 104 lentivirally in-
fected cells. Cells were then placed in a 
37°C and 5% CO2 incubator. Colonies 
were allowed to grow over the course of 
2 wk. After MTT treatment for 4 h, colo-
nies were counted under a microscope 
(Nikon Eclipse Ti; Melville, NY). All assays 
were performed in triplicate.
Generation of a phospho-PAK1 (S223) antibody
Mouse studies were performed in accordance with the policies of 
the George Washington University Institutional Animal Care and 
Use Committee (IACUC protocol A257). Peptides based on the hu-
man PAK1 sequence (214–227; TRDVATSPI-pSer-PTEN) were syn-
thesized by solid state synthesis, conjugated to keyhole limpet 
hemocyanin (KLH; Biomatik), and used for immunization. All mice 
were obtained from the Jackson Laboratory (Bar Harbor, ME). After 
three intraperitoneal injections, antiserum was obtained from the 
cardiac blood of the mice and tested with indirect enzyme-linked 
immunosorbent assay against free peptide, peptide-KLH, and KLH.
Lentiviral infection
Lentiviral expression vectors for wild-type PAK1-GFP and mutant 
PAK1S223A-GFP were constructed by subcloning corresponding 
cDNAs into pLV-puro lentiviral vector, as described previously (Shin 
and Kim, 2012). Lentiviral short hairpin RNAs (shRNAs) specific for 
CK2α (NM_177559) were obtained from Sigma-Aldrich (MISSION 
shRNA; St. Louis, MO). Biologically active shRNAs were generated 
from the pLKO.1-puro vector, utilizing the Polymerase III U6-RNA 
promoter. Transfection was performed as described previously (Shin 
and Kim, 2012).
due to overexpression of PAK1, but rather is due to the conversion 
of PAK1 to a hyperactive form, and thus strongly support our find-
ing that this conversion is mediated by CK2-dependent PAK1 phos-
phorylation. It is interesting to note that PDK1 phosphorylation of 
PAK1 at T423 is involved in actin polymerization in normal cells 
(King et al., 2000), but does not significantly affect tumor cell growth 
(Lu et al., 2010). In addition, overexpression of the artificially acti-
vated PAK1 mutant, PAK1T423E, leads to stimulation of anchorage-
independent growth in breast cancer cell lines (Vadlamudi et al., 
2000) and breast carcinomas in transgenic mice (Wang et al., 
2006a); however, it does not suffice to draw clinically relevant con-
clusions (Kichina et al., 2010). These observations might highlight 
the significance of CK2 phosphorylation of S223 in regulating PAK1 
activity. PAK1 overexpression appears to be sufficient to induce ma-
lignant transformation of prostate epithelial cells, but blocking 
PAK1S223 phosphorylation leads to growth inhibition of the tumor 
cells (Figure 6). These findings reinforce the view that PAK1 activa-
tion in prostate cancer cells may rely on CK2 activity. CK2 level is 
increased in most tumor tissues and acts as an anti-apoptotic and 
prosurvival agent that confers a number of selective advantages to 
tumor cells. In this sense, our findings establish that PAK1 phospho-
rylation by CK2 may play a fundamental role in the activation and 
perpetuation of PAK1 oncogenic signaling, as expression of PAK1 
targets is robust in cancer cells.
FIGURE 5: CK2-dependent PAK1 phosphorylation is critical for growth of the prostate cancer 
PC3 cells. (A) Cell extracts of PC3 cells with (sh1) or without (NT) CK2α knockdown were 
subjected to Western blot analysis with anti-pPAK1S144, anti-PAK1S199, anti-PAK1, anti-CK2α, or 
anti-actin antibody. (B) PC3 cells with (sh1) or without (NT) CK2α knockdown were incubated for 
1 d in the absence of serum and then cultured in the presence (+) or absence (−) of EGF 
(100 ng/ml) for 1 h, and total cell extracts were subjected to Western blot analysis with 
anti-pPAK1S223, anti-PAK1S144, anti-CK2α, or anti-actin antibody. (C) Western blot analysis of 
expression of PAK1 and PAK2 in PC3 cells with (sh1 and sh2) or without (NT) PAK1 or PAK2 
knockdown (left) and MTT proliferation assay of the PC3 cells (right).
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ATP), the beads were mixed with purified CK2 kinase (20 ng) and 
0.5 μCi of [32P]γ-ATP and incubated at 30°C for 30 min. For in vivo 
protein phosphorylation assay, 293T cells were first starved for phos-
phate in phosphate-free DMEM containing 10% FBS for 2 h. The 
medium was again replaced with fresh phosphate-free medium and 
Protein phosphorylation and Western blot assays
For in vitro protein phosphorylation assay, GST-PAK1 proteins were 
harvested from Escherichia coli cell extracts with glutathione Sep-
harose 4B beads. After being equilibrated with kinase buffer (20 mM 
HEPES, pH 7.0, 10 mM MgCl2, 1 mM dithiothreitol, 100 μM cold 
FIGURE 6: S223A mutation abrogates PAK1-mediated malignant transformation of prostate epithelial cells in vitro and 
in vivo. The benign prostate RWPE-1 cells infected with lentivirus expressing the vector plasmid, GFP-PAK1, or 
GFP-PAK1S223A (S223A) were used for experiments shown in (A) through (E). (A) Focus-formation assays. Quantitative 
analysis of foci numbers (mean ± SD) in week 3 (n = 4). (B) Anchorage-independent growth assay. Cells (RWPE-1) 
expressing GFP-vector, GFP-PAK1 (WT), or GFP-PAK1S223A (S223A) were visualized by phase-contrast (Phase) and 
fluorescence (GFP) microscopy. Quantitative analysis of colony numbers (mean ± SD) in week 3 is shown (n = 4). 
(C) Invasion assay. The invasion rate was determined by counting the cells that migrated through BME-coated inserts in 
the Transwell Boyden chamber and expressed as the percentage relative to control (vector). Each bar represents the 
mean ± SD of five fields counted. (D) Tumor growth determined by measuring the volumes of each tumor every 7 d 
after injection, as described in Materials and Methods. (E) The average tumor weight (left) and the representative 
tumors (right) of the GFP-PAK1 (WT) group mice killed 6 wk after injection. (F and G) Tumor tissues dissected from the 
mice (E) were stained with anti-Ki67, anti-CD31, or anti-pPAK1S223 antibody. Nuclei were stained with DAPI (blue).
2998 | Y. J. Shin et al. Molecular Biology of the Cell
washed, slides were incubated with 5% goat serum to reduce 
nonspecific background staining. Finally, the slides were incubated 
with anti-Ki67 and CD31 antibodies. Tumor tissue images were 
taken by a Nikon Eclipse Ti inverted microscope and analyzed 
using the NIS-Elements BR software. For immunofluorescence 
staining, the slides were incubated with anti-pPAK(Ser223) anti-
body for 2 d at 4°C. After being washed, they were incubated with 
Alexa Fluor 594 goat anti-mouse immunoglobulin G at a 1/2000 
dilution for 1 h. After being mounted with mounting medium 
containing 4′,6-diamidino-2-phenylindole (DAPI [H-1200]; Vector 
Laboratories, Burlingame, CA), the cells were photographed using 
a fluorescence microscope (IX71 microscope; Olympus Imaging 
America).
Statistics
In all experiments, statistical significance was defined by p values: *, 
p < 0.05; **, p < 0.005; ***, p < 0.001 (as compared with control).
500 μCi of [32P]orthophosphate per 100-mm dish, and cells were 
incubated at 37°C for 6 h. GST-PAK1 proteins were resolved by 
SDS–PAGE and subjected to autoradiography. Western blot analy-
sis was performed, as described previously (Shin and Kim, 2012).
MTT cell proliferation and primary focus formation assays
For MTT cell proliferation assay, cell growth was evaluated by re-
placing the culture media with 200 μl of 0.5 mg/ml MTT media solu-
tion after incubation for 1–4 d. For primary-focus formation assays, 
RWPE-1 cells were plated at a density of 2 × 105 cells/well on a 
six-well plate. The next day, cells were transiently transfected with 
100 ng of plasmids encoding GFP-PAK1 or GFP-PAK1S223A, and the 
appearance of PAK1-induced foci of transformed cells was quanti-
tated after 14 d of transfection. Cell invasion was performed as de-
scribed previously (Shin and Kim, 2012).
Tumor xenograft assay
All mouse studies were performed in accordance with the policies of 
the George Washington University Institutional Animal Care and 
Use Committee (IACUC protocol A244). Xenografts were carried 
out by a flank subcutaneous injection of 5- to 6-wk-old athymic (nu/
nu) nude mice (Jackson Laboratory) with 4 × 106 of RWPE-1 cells 
(200 μl) infected with control, GFP-PAK1, or GFP-PAK1S223A plasmid 
(n = 8 for each group). For injection, RWPE-1 cells were suspended 
in a 1:1 solution of growth media Matrigel matrix. Tumor size was 
measured, and tumor volumes were calculated using the formula: 
tumor volume = (W2 × L)/2, where W is width and L is length in mm. 
Xenograft tumor tissues were Formalin-fixed and embedded in par-
affin, as described previously (Wang et al., 2006a).
Immunohistochemistry
Xenograft tumor tissues were Formalin-fixed and embedded in 
paraffin, as described previously (Shin and Kim, 2012). Seven-
micron-thick serial sections were cut from paraffin blocks, mounted 
on acid-cleaned glass slides, and heated at 55°C for 60 min. After 
deparaffinization and rehydration, tissue section slides were 
blocked for endogenous peroxidase in 3% H2O2 in methanol for 
20 min. Slides were incubated with 10 mM citrate buffer (pH 6.0) at 
95–100°C for 20 min and allowed to cool for 30 min. After being 
FIGURE 7: A proposed model for the role of PAK1S223 
phosphorylation in PAK1 activation. PAK1 activation involves 
conformational changes that lead to the conversion of an inactive 
dimeric PAK1 to an active monomeric form. This conversion, however, 
is not sufficient to bring about PAK1 activation; it is required for PAK1 
phosphorylation at S223 by CK2. This phosphorylation is thought to 
lock the PAK1 kinase domain in a catalytically competent form. S223 
phosphorylation does not directly affect phosphorylation of T423; 
however, the possibility is not excluded that CK2 might activate PDK1 
by activating the PI3K/Akt signaling via PTEN and positively regulate 
T423 phosphorylation.
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